This segment is dedicated to the research and development of novel therapeutics for Alzheimer's disease, focusing on disease-modifying approaches. The primary focus is on targeting soluble amyloid-beta oligomers (AβOs), believed to be a key driver of Alzheimer's pathology. The lead drug candidate, ACU193, an immunotherapy, is currently in Phase 1 clinical trials. Research efforts involve preclinical studies, biomarker identification, and clinical trial design to assess the safety, tolerability, and efficacy of ACU193. The goal is to develop treatments that can slow or halt the progression of Alzheimer's disease, improving cognitive function and quality of life for patients. Future opportunities include expanding the pipeline with additional therapeutic candidates and exploring combination therapies.